• +1-646-491-9876
    • +91-20-67278686

    Search

    Premature Labor (Tocolysis) - Pipeline Review, H1 2017

    Premature Labor (Tocolysis) - Pipeline Review, H1 2017

    • Report Code ID: RW0001709456
    • Category Pharmaceuticals
    • No. of Pages 49
    • Publication Month Mar-17
    • Publisher Name Global Markets Direct
    Premature Labor (Tocolysis) - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Premature Labor (Tocolysis) - Pipeline Review, H1 2017, provides an overview of the Premature Labor (Tocolysis) (Women's Health) pipeline landscape.

    Preterm labor or premature labor is defined as labor that begins before completion of 36 weeks of pregnancy. Symptoms include sensation of pelvic or lower abdominal pressure, mild abdominal cramps, diarrhea, vaginal spotting or bleeding and constant low, dull backache. Treatment includes corticosteroids and tocolytics.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Premature Labor (Tocolysis) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Premature Labor (Tocolysis) (Women's Health) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Premature Labor (Tocolysis) (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Premature Labor (Tocolysis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 2, 1 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

    Premature Labor (Tocolysis) (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Premature Labor (Tocolysis) (Women's Health) .
    - The pipeline guide reviews pipeline therapeutics for Premature Labor (Tocolysis) (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Premature Labor (Tocolysis) (Women's Health) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Premature Labor (Tocolysis) (Women's Health) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Premature Labor (Tocolysis) (Women's Health)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Premature Labor (Tocolysis) (Women's Health) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Premature Labor (Tocolysis) (Women's Health) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Premature Labor (Tocolysis) - Overview
    Premature Labor (Tocolysis) - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Premature Labor (Tocolysis) - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Premature Labor (Tocolysis) - Companies Involved in Therapeutics Development
    AMAG Pharmaceuticals Inc
    GlaxoSmithKline Plc
    Juniper Pharmaceuticals Inc
    Kissei Pharmaceutical Co Ltd
    Lipocine Inc
    ObsEva SA
    Premature Labor (Tocolysis) - Drug Profiles
    bedoradrine sulfate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    hydroxyprogesterone caproate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    hydroxyprogesterone caproate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    OBE-022 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    progesterone - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    retosiban - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule for Acute Inflammation and Premature Labor - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Agonize Progesterone Receptor for Preterm Birth - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules for Premature Labor - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Premature Labor (Tocolysis) - Dormant Projects
    Premature Labor (Tocolysis) - Discontinued Products
    Premature Labor (Tocolysis) - Product Development Milestones
    Featured News & Press Releases
    Feb 02, 2017: AMAG Pharmaceuticals Announces Positive Topline Results from Definitive Pharmacokinetic Study for Makena Subcutaneous Administration
    Jan 13, 2017: ObsEva Announces Completion of Phase 1 First-in-Women Study of OBE022 for the Treatment of Preterm Labor
    Jan 09, 2017: Lipocine Receives FDA Guidance on the Phase 3 Program for LPCN 1107, an Oral Alternative for the Prevention of Preterm Birth
    Oct 12, 2016: AMAG Pharmaceuticals Announces Achievement of Key Milestone in Next Generation Development Program for Makena
    Jul 28, 2016: ObsEva Initiates Phase 1 Clinical Program of OBE022, a First-in-Class Orally Active Prostaglandin F2a Antagonist, for the Treatment of Preterm Labor
    Apr 04, 2016: AMAG Pharmaceuticals Announces the U.S. Commercial Launch of New Single-Dose, Preservative-Free Makena (hydroxyprogesterone caproate injection)
    Feb 23, 2016: AMAG Pharmaceuticals Announces FDA Approval of New Single-Dose, Preservative-Free Makena (hydroxyprogesterone caproate injection)
    Feb 16, 2016: Lipocine Reports Positive Results of Multi-Dose Pharmacokinetic Study of LPCN 1107 for the Prevention of Preterm Birth in Pregnant Women
    Jan 11, 2016: Juniper Pharmaceuticals provides Update on JNP-0301
    Nov 23, 2015: AMAG Pharmaceuticals Responds to Recent Complete Response Letter From the FDA for the Single-Dose, Preservative-Free Vial of Makena
    Nov 18, 2015: AMAG Pharmaceuticals Receives Complete Response Letter From FDA for Single-Dose, Preservative-Free Vial of Makena (hydroxyprogesterone caproate injection)
    Nov 04, 2015: ObsEva Presents Pharmacology Data Showing that OBE002, the First Orally Active Prostaglandin F2a Antagonist, is devoid of the side effects associated with NSAID treatment of Preterm Labor
    May 28, 2015: AMAG Pharmaceuticals Receives Complete Response Letter From FDA for the Single-Dose Vial of Makena
    May 20, 2015: AMAG Pharmaceuticals Expands Resources Dedicated to Reducing the Risk of Preterm Birth
    Mar 17, 2015: GSK announces start of phase III programme to evaluate retosiban for spontaneous preterm labour
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Premature Labor (Tocolysis) , H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Premature Labor (Tocolysis) - Pipeline by AMAG Pharmaceuticals Inc, H1 2017
    Premature Labor (Tocolysis) - Pipeline by GlaxoSmithKline Plc, H1 2017
    Premature Labor (Tocolysis) - Pipeline by Juniper Pharmaceuticals Inc, H1 2017
    Premature Labor (Tocolysis) - Pipeline by Kissei Pharmaceutical Co Ltd, H1 2017
    Premature Labor (Tocolysis) - Pipeline by Lipocine Inc, H1 2017
    Premature Labor (Tocolysis) - Pipeline by ObsEva SA, H1 2017
    Premature Labor (Tocolysis) - Dormant Projects, H1 2017
    Premature Labor (Tocolysis) - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Premature Labor (Tocolysis) , H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    AMAG Pharmaceuticals Inc
    GlaxoSmithKline Plc
    Juniper Pharmaceuticals Inc
    Kissei Pharmaceutical Co Ltd
    Lipocine Inc
    ObsEva SA

    Request for Sample

    Report Url http://www.reportsweb.com//premature-labor-tocolysis-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//premature-labor-tocolysis-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//premature-labor-tocolysis-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments